Large-scale testing (Phase 3)Active Not RecruitingNCT02785952
What this trial is testing
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Who this might be right for
Recurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma AJCC v7
SWOG Cancer Research Network 275